Antipsychotic Drugs Companies

Intra-Cellular Therapies Received FDA approval for Caplyta (lumateperone) as adjunctive therapy for depressive episodes associated with bipolar I or II disorder, expanding its market reach.

Alkermes Announced positive results from ENLIGHTEN-early, a Phase 3b study evaluating LYBALVI for schizophrenia, providing further evidence for its efficacy and tolerability.

Luye Pharma Group Secured FDA approval for Rykindo for the treatment of schizophrenia and bipolar 1 disorder, offering a new option with a once-daily dosing schedule.

Otsuka Pharmaceutical Co., Ltd. and Lundbeck Received FDA approval for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents (13-17 years old), addressing a crucial need in this underserved population.

List of Antipsychotic Drugs Key Companies in the Market

• 
  

  Johnson and Johnson (U.S.)

  
  


• 
  

  GlaxoSmithKline Plc. (U.K.)

  
  


• 
  

  Pfizer Inc. (U.S.)

  
  


• 
  

  AstraZeneca (U.K.)

  
  


• 
  

  Bristol-Myers Squibb (U.S.)

  
  


• 
  

  Eli Lily & Co. (U.S.)